Evidence map›Paper›PMID 27609828›Full record

ArticleGut2017

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.

Emilie Crouchet, Mathieu Lefèvre, Eloi R Verrier, Marine A Oudot, Thomas F Baumert, Catherine Schuster

Open access · hybridAbstract read
In one paragraph

Article in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Apolipoprotein E Signals via TLR4 to Induce CXCL5 Secretion by Asthmatic Airway Epithelial Cells.American journal of respiratory cell and molecular biology · 2020
    Article
  5. Article
  6. The Role of ApoE in HCV Infection and Comorbidity.International journal of molecular sciences · 2019
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Emilie CrouchetINSERM, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Mathieu LefèvreINSERM, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Eloi R VerrierINSERM, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Marine A OudotINSERM, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Thomas F BaumertINSERM, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Catherine SchusterINSERM, UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France.
Institute for Translational Medicine and Liver DiseaseInserm · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe HCV life cycle and the lipid metabolism are inextricably intertwined. In the blood, HCV virions are associated with lipoproteins, forming lipoviroparticles (LVPs), which are the most infectious form of the virus. Apolipoprotein E (apoE), a key LVP component, plays an essential role in HCV entry, assembly and egress. ApoE is also a cell host factor involved in lipoprotein homeostasis. Although the majority of apoE is associated with lipoproteins, a lipid-free (LF) form exists in blood. However, the role of LF-apoE in both lipid metabolism and HCV life cycle is poorly understood.

designIn this study, using the cell culture-derived HCV model system in human hepatoma Huh7.5.1 cells and primary human hepatocytes (PHH), we investigated the effect of LF-apoE on the early steps of HCV life cycle and on the lipid metabolism of hepatic cells.

resultsA dose-dependent decrease in HCV replication was observed when Huh7.5.1 cells and PHH were treated with increasing amounts of LF-apoE. We showed that LF-apoE acts on HCV replication independently of previously described apoE receptors. We observed that LF-apoE induced a marked hepatic cholesterol efflux via the ATP-binding cassette subfamily G member 1 (ABCG1) protein that in turn inhibits HCV replication. LF-apoE also increases both apolipoprotein AI and high-density lipoprotein production.

conclusionsOur findings highlight a new mechanism in lipid metabolism regulation and interaction of the lipid metabolism with the HCV life cycle, which may be important for viral pathogenesis and might also be explored for antiviral therapy.

Indexed as

Apolipoprotein A-IApolipoproteins EATP Binding Cassette Transporter, Subfamily G, Member 1Cell Line, TumorCholesterolDose-Response Relationship, DrugHepacivirusHepatocytesHumansLife Cycle StagesLipoproteins, HDLMembrane MicrodomainsVirus InternalizationVirus ReplicationABCG1 protein, humanApolipoprotein A-IApolipoproteins EATP Binding Cassette Transporter, Subfamily G, Member 1CholesterolLipoproteins, HDLHCVLIPID METABOLISMLIPOPROTEIN-CHOLESTEROLLIPOPROTEIN METABOLISM

Identifiers

PMID27609828
PMCPMC5531222
OpenAlexW2515002988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.